rs121912502
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PP3_ModerateBS2
The NM_000236.3(LIPC):c.866C>T(p.Ser289Phe) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00115 in 1,614,162 control chromosomes in the GnomAD database, including 3 homozygotes. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Synonymous variant affecting the same amino acid position (i.e. S289S) has been classified as Benign.
Frequency
Consequence
NM_000236.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
LIPC | NM_000236.3 | c.866C>T | p.Ser289Phe | missense_variant | 6/9 | ENST00000299022.10 | NP_000227.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
LIPC | ENST00000299022.10 | c.866C>T | p.Ser289Phe | missense_variant | 6/9 | 1 | NM_000236.3 | ENSP00000299022.5 |
Frequencies
GnomAD3 genomes AF: 0.000710 AC: 108AN: 152206Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00101 AC: 255AN: 251294Hom.: 1 AF XY: 0.000994 AC XY: 135AN XY: 135872
GnomAD4 exome AF: 0.00119 AC: 1746AN: 1461838Hom.: 3 Cov.: 33 AF XY: 0.00120 AC XY: 875AN XY: 727214
GnomAD4 genome AF: 0.000709 AC: 108AN: 152324Hom.: 0 Cov.: 32 AF XY: 0.000698 AC XY: 52AN XY: 74490
ClinVar
Submissions by phenotype
Hyperlipidemia due to hepatic triglyceride lipase deficiency Pathogenic:1Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Oct 16, 2014 | The p.Ser289Phe variant in LIPC has been reported in 1 compound heterozygous individual with hepatic lipase deficiency and segregated with disease in 3 affected compound heterozygous relatives from 1 family (Hegele 1991). This variant has been identified in 0.13% (11/8584) of European American chromosomes and 0.05% (4/4384) of African American chromosomes by the NHLBI Exome Sequencing Project (http://evs.gs.washington.edu/EVS/; dbSNP rs121912502). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a recessive carrier frequency. In vitro assays indicate the p.Ser289Phe variant leads to reduced LIPC activity (Durstenfeld 1994). However, these types of assays may not accurately represent biological function. Computational prediction tools and conservation analysis also suggest that the p.Ser289Phe variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, while there is some suspicion for a pathogenic role, the clinical significance of the p.Ser289Phe variant is uncertain. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. However, the evidence from the literature, in combination with allele frequency data from public databases where available, was not sufficient to rule this variant in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Aug 30, 1991 | - - |
not provided Uncertain:1Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jul 27, 2023 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Mar 15, 2024 | PP3, PP4, PM1_supporting, PS3_supporting - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at